Scholarlink

Objective <p>This study aimed to develop sodium alginate-hyaluronic acid (SA-HA) composite microspheres for targeted doxorubicin (DOX) delivery in hepatocellular carcinoma (HCC) treatment. The research sought to address key limitations of current transcatheter arterial chemoembolization (TACE) agents by combining SA’s mechanical stability with HA’s tumor-targeting capability, while optimizing drug loading and release kinetics.</p> Results <p>The SA-HA microspheres exhibited enhanced physicochemical properties, including 28.4% lower porosity (SEM) and 3.6-fold higher swelling capacity (5.42% at 6&#xa0;h) compared to SA controls. FTIR confirmed successful ionic crosslinking, while drug loading efficiency reached 89.2% - significantly higher than conventional SA systems. In vitro release studies demonstrated sustained DOX release (85.2 ± 3.1% at 24&#xa0;h, first-order kinetics R² = 0.95), with superior cytotoxicity against HepG2 cells (IC50 = 0.48 ± 0.03&#xa0;µg/mL vs. free DOX 1.12 ± 0.05&#xa0;µg/mL, <i>p</i> &lt; 0.05). These results validate SA-HA microspheres as a promising TACE-compatible platform for HCC therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sodium alginate-hyaluronic acid composite particles for doxorubicin delivery: in vitro characterization and cytotoxicity evaluation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月30日

查看全文
  • Zhiyu She,
  • Fangxia Zhang,
  • Duanfei Li,
  • Yong Ji

摘要

Objective

This study aimed to develop sodium alginate-hyaluronic acid (SA-HA) composite microspheres for targeted doxorubicin (DOX) delivery in hepatocellular carcinoma (HCC) treatment. The research sought to address key limitations of current transcatheter arterial chemoembolization (TACE) agents by combining SA’s mechanical stability with HA’s tumor-targeting capability, while optimizing drug loading and release kinetics.

Results

The SA-HA microspheres exhibited enhanced physicochemical properties, including 28.4% lower porosity (SEM) and 3.6-fold higher swelling capacity (5.42% at 6 h) compared to SA controls. FTIR confirmed successful ionic crosslinking, while drug loading efficiency reached 89.2% - significantly higher than conventional SA systems. In vitro release studies demonstrated sustained DOX release (85.2 ± 3.1% at 24 h, first-order kinetics R² = 0.95), with superior cytotoxicity against HepG2 cells (IC50 = 0.48 ± 0.03 µg/mL vs. free DOX 1.12 ± 0.05 µg/mL, p < 0.05). These results validate SA-HA microspheres as a promising TACE-compatible platform for HCC therapy.